Masaki Kanazu

10PUBLICATIONS
12CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 19, 2023
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.

Mototsugu Shimokawa, Masaki Kanazu, Ryusei Saito

|Nov 21, 2022
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).

Shinya Uematsu, Satoru Kitazono, Hisashi Tanaka

|Jul 12, 2022
Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study.

Yuki Akazawa, Aki Yoshikawa, Masaki Kanazu

|May 11, 2021
Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Tomoki Kuge, Fukuko Okabe, Yuji Yamamoto

|Mar 08, 2021
EGFR-mutant lung adenocarcinoma associated with antisynthetase syndrome successfully treated with osimertinib.

Reina Hara, Masaki Kanazu, Ami Iwai

|Oct 30, 2020
Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.

Masaki Kanazu, Masahide Mori, Madoka Kimura

Pageof 2

Frequent Collaborators

2 joint publications

Tomoki Kuge

1 joint publications

Ryuya Edahiro

1 joint publications

Katsuya Hirano

1 joint publications

Yuji Yamamoto